Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Core Insights - Nkarta, Inc. is advancing its NKX019 clinical trials for autoimmune diseases, with patient enrollment for the Ntrust-2 trial expected to begin by the end of 2024 [5][4] - The company reported a cash balance of $426.7 million as of June 30, 2024, which is projected to fund operations into late 2027 [9][8] - Preliminary clinical data from the Ntrust-1 and Ntrust-2 trials is anticipated in 2025 [5] Clinical Development - NKX019 is being developed for the treatment of systemic sclerosis, myositis, and vasculitis, with the Ntrust-2 trial receiving FDA clearance [4][11] - The dosing regimen for Ntrust-2 involves three doses of NKX019 on Days 0, 3, and 7 following lymphodepletion with cyclophosphamide [4][13] - An investigator-sponsored trial of NKX019 in systemic lupus erythematosus is also set to begin, with a similar dosing schedule [4][12] Financial Performance - For the second quarter of 2024, Nkarta reported R&D expenses of $23.1 million and G&A expenses of $7.6 million [8] - The net loss for the second quarter was $25.0 million, equating to $0.34 per share [8][19] - Cash and cash equivalents are expected to be sufficient to support the company's operating plan through late 2027 [9] Leadership Updates - In July 2024, Nadir Mahmood joined as President, and David R. Shook was promoted to Chief Medical Officer [7] - George Vratsanos joined the Board of Directors in June 2024, bringing expertise in immunology and autoimmunity [7] About NKX019 - NKX019 is an allogeneic, cryopreserved immunotherapy candidate utilizing engineered NK cells for enhanced targeting and persistence [10] - The therapy aims to reset the immune system by eliminating pathogenic B cells, potentially leading to long-term remissions in autoimmune diseases [11]